SCHEMBL1428258

SCHEMBL1428258

CCC(=CCCN(CC)CC)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 3/20 0.37
GRIK2 Q13002 2/20 0.37
ALDH1A1 P00352 2/20 0.35
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
EP300 Q09472 1/20 0.31
LMNA P02545 2/20 0.30
POLB P06746 1/20 0.30
KDM4E B2RXH2 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
CPB1 P15086 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278815 0.89 GRIK1 (0.40) GRIK1GRIK2ALDH1A1CHRM2CHRM4
SCHEMBL9644125 0.83 ALDH1A1 (0.36) GRIK1GRIK2ALDH1A1
SCHEMBL3278162 0.83 GRIK1 (0.42) GRIK1GRIK2CHRM2EP300LMNA
SCHEMBL5488690 0.82 GRIK1 (0.33) GRIK1GRIK2ALDH1A1
SCHEMBL1921773 0.82 GRIK1 (0.38) GRIK1GRIK2EP300CPB1
SCHEMBL3277773 0.80 EP300 (0.44) GRIK1CHRM1EP300LMNAPOLB
SCHEMBL3282826 0.80 EP300 (0.44) GRIK1CHRM1EP300LMNAPOLB
SCHEMBL3284713 0.80 EP300 (0.44) GRIK1CHRM1EP300LMNAPOLB
SCHEMBL37961 0.78 ALDH1A1 (0.36) ALDH1A1CHRM2CHRM4CHRM5CHRM1
SCHEMBL37962 0.78 ALDH1A1 (0.36) ALDH1A1CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300067-B1 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIV OF BELFAST (GB) 2017-10-25 EP claimed
US-20160136286-A1 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2016-05-19 US claimed
US-9271928-B2 Drug delivery composition THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2016-03-01 US claimed
US-20110165114-A1 DRUG DELIVERY COMPOSITION QUEEN'S UNIVERSITY OF BELFAST, THE (GB) 2011-07-07 US claimed
EP-2300067-A2 DRUG DELIVERY COMPOSITION The Queen's University of Belfast (GB) 2011-03-30 EP claimed
WO-2009147372-A2 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2009-12-10 WO claimed
US-20070113353-A1 Polymeric Surface Treatment Compositions THE CLOROX COMPANY 2007-05-24 US claimed
EP-2300067-B1 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIV OF BELFAST (GB) 2017-10-25 EP disclosed
US-20160136286-A1 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2016-05-19 US disclosed
US-9271928-B2 Drug delivery composition THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2016-03-01 US disclosed
US-8450359-B2 Polymer-supported photosensitizers for the generation of singlet oxygen THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2013-05-28 US disclosed
US-20110165114-A1 DRUG DELIVERY COMPOSITION QUEEN'S UNIVERSITY OF BELFAST, THE (GB) 2011-07-07 US disclosed
EP-2300067-A2 DRUG DELIVERY COMPOSITION The Queen's University of Belfast (GB) 2011-03-30 EP disclosed
US-20100160487-A1 Polymeric Surface Treatment Compositions THE CLOROX COMPANY (US) 2010-06-24 US disclosed
US-7699941-B2 Polymeric surface treatment compositions THE CLOROX COMPANY (US) 2010-04-20 US disclosed
WO-2009147372-A2 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2009-12-10 WO disclosed
US-20090292357-A1 MATERIAL AND USES THEREOF THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2009-11-26 US disclosed
EP-1984439-A1 MATERIAL AND USES THEREOF The Queen's University of Belfast (GB) 2008-10-29 EP disclosed
WO-2007088392-A1 MATERIAL AND USES THEREOF THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2007-08-09 WO disclosed
US-20070113353-A1 Polymeric Surface Treatment Compositions THE CLOROX COMPANY 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165114-A1 DRUG DELIVERY COMPOSITION ECPAS, ABCB11, ABCB1 GRIK1 2170/4885GRIK2 2976/4885ALDH1A1 1965/4885
US-20160136286-A1 DRUG DELIVERY COMPOSITION ECPAS, ABCB11, ABCB1 GRIK1 2170/4885GRIK2 2976/4885ALDH1A1 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.